Water insoluble drugs coated by coacervated fish gelatin.
Abstract
According to this invention, the combination of a solid particulate water insoluble drug with a solid fish gelatin coating is produced by coacervation of the fish gelatin. The fish gelatin being soluble at ambient temperatures provides a basis for relatively low temperature coacervati on impossible with other gelatins. Coacervation is brought about by the addition of conventional coacervation agents and the coacervating suspension containing gelatin and the agents is rendered insoluble by the addition of a suitable fixative such as glutaraldehyde.
Term
Term ended
Projected expiry passed 14 June 2009, 17.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
10 claims: 11 independent, 0 dependent
- 1A combination comprising, a solid particulate water insoluble drug with a solid fish gelatin coating surrounding said drug.
- 2The combination of Claim 1 wherein fish gelatin includes a coacervating agent.
- 3The combination of Claim 1 wherein the coacervating agent is selected from the group consisting of edible sulfate and edible alcohols.
- 6A process for coacervating fish gelatin to form a water insoluble coating around a water insoluble drug comprising:a) slowly adding a coacervating agent to an aqueous solution of fish gelatin until the gelatin forms a suspension;and b) contacting the suspension with a fixative to form individual particles of water insoluble fish gelatin.
- 7The process of Claim 6 wherein the coacervating agent is selected from the group consisting of edible sulfates and alcohols.
- 9The process of Claim 6 wherein a particulate water insoluble drug is suspended in the aqueous solution prior to the addition of the coacervating agent.
- 10Use of fish gelatin to form a water insoluble coating around a water insoluble drug by coacervation with a coacervating agent and fixation by a fixative.
Independent claims10
19 paragraphs in 5 sections, as filed
0001Many attempts have been made in the past to mask or eliminate noxious odors and tastes of drugs to enhance the dosage compliance of patients who are required to take these drugs. Coatings which have been used in the case of solid water insoluble particulates have all suffered from deficiencies of one sort or another relating either to processing difficulties and working with the coating materials themselves or from limited success in performing the masking function.
0002One method of dealing with drugs of this sort is to coat them in the form of microparticles. The coating of particles by coacervation is well known. U.S. Patent 3,594,327 issued to Julius G. Beesey discloses a process for making minute capsules in which minute particles of water and miscible material and hydrophilic film forming polymeric material such as gelatin are dispersed in water and coacervated so that the polymeric material deposits around each of the minute particles. The polymeric material is then rendered rigid and water insoluble by a suitable fixative such as copper sulfate. The concept of coacervation of gelatin around particulate matter is also described in U.S. Patent 3,317,434 issued to Vels et al. and U.S. Patent 3,176,001 also issued to Vels. This gelatin which is of the porcine bovine type, is also used to form gelatin capsules and for some granulations.
0003While coacervation of conventional bovine and porcine gelatin is known, commercial processes utilizing coacervation of bovine and porcine gelatin as a coating for water insoluble drug particles is essentially nonexistent. The reason for this is that the gelatin must be heated to approximately 40°C before it is dissolved and ready for use. This temperature may adversely effect heat labile drugs and the increased temperature also makes the process difficult to work with.
0004Teleostean (fish) gelatin however is soluble in water at room temperature. This gelatin described for example in "Production of Glue and Gelatin from Fish" by J. C. Kernot and N. E. Speer, Department of Sol Ind. Research 2nd report of Adhesives Research Committee 1926, 23-33. Fish gelatin is also mentioned in U.S. Patent 2,560,011 which teaches an extraction process for it. U.S. Patent 3,873,749 issued to Carpenter et al. teaches a process for manufacturing a fish gelatin-alginate composition.
SUMMARY OF THE INVENTION
0005According to this invention, the combination of a solid particulate water insoluble drug with a solid fish gelatin coating is produced by coacervation of the fish gelatin. The fish gelatin being soluble at 5 - 10°C provides a basis for ambient temperature e.g. 16-27°C coacervation impossible with other gelatins. Coacervation is brought about by the addition of conventional coacervation agents and the coacervating suspension containing gelatin and the agents is rendered insoluble by the addition of a suitable fixative such as glutaraldehyde.
DETAILED DESCRIPTION OF THE INVENTION
0006This invention is directed to the coacervation of fish gelatin to form microparticles. These microparticles are particularly useful as a means for protecting particulate water insoluble drugs from exposure to oxygen or moisture and the barrier thus formed is also useful for masking of unpleasant taste and odor from such drugs. The process of this invention is particularly useful for drugs which are heat sensitive because of the low temperature water solubility of fish gelatin.
0007While all drugs which are water insoluble particulates may be used and benefit from the process of this invention, drugs as defined herein specifically exclude water insoluble particulate ion exchange resins such as cholystyramine. Cholystyramine, has thus far, proven resistant to coacervation. While not wishing to be bound by any theory it is postulated that the charge associated with the ion exchange resin is the reason for the difficulty in obtaining no satisfactory coacervation.
0008The process of this invention employs reagents useful for coacervation, either porcine or bovine gelatin. These reagents which are for example, lower alkyl alcohols such as ethanol, or short chained glycols, and inorganic salts such as sodium sulfate, when reacted with fish gelatin solutions coacervate the fish gelatin to provide particles which are insoluble in the modified aqueous solution. The subsequent addition of a fixative-cross linking agent such as glutaraldehyde renders the fish gelatin water insoluble. The insoluble particles can then be removed or collected from aqueous solution by conventional techniques such as ultracentrifugation, or filtration or the like. These harvested particles can be collected for conventional oral dosage forms.
0009Examples of the product of this invention follow. In all instances fish gelatin solution was obtained from Norlund Products Inc., New Brunswick, New Jersey. Fish gelatin contained 45% solids in solution.
EXAMPLE 1
0010A fish gelatin solution containing 6 grams of fish gelatin at a 45% solids ratio was diluted with 54 mls of water and was mixed together with 56 ml aliquot of 20% of sodium sulfate which was added drop wise to the stirred solution over approximately 10 minutes.
0011After stirring for approximately 1/2 hour 1 ml of 5% v/v glutaraldehyde was added. After 3-1/2 minutes 60 mls of a 12% weight by weight solution of sodium metabisulfite was added to reduce the glutaradehyde to an alcohol to prevent further reaction.
0012The hardened soluble particles have a variety of size ranges with many below the 1 micron range. Particles below the micron range were not successfully harvested by filtration through a nylon 66 filter with a pore size of 0.45u. The filter was however useful in sorting the larger particles.
0013It should be noted that particles of all sizes were prepared with sodium sulfate and then successfully harvested by lyophilization. In addition, particles in the 100nm range have been harvested by ultracentrifugation after first sorting the larger particles using centrifugation at lower speeds. It should further be noted that particles prepared by ultracentrifugation and lyophilization can be resuspended in water and do not form aggregates.
EXAMPLE 2
0014This example utilizes coacervation by ethanol. 12 grams of the 45% solid solution of fish gelatin was dissolved in 324 mls of distilled water. 500 mls of 95% ethanol was added drop wise with stirring over a period of approximately 1/2 hour, and the suspension was stirred for another 1/2 hour. Subsequently, 45 mls of 12.5% v/v of glutaraldehyde was added, and, after 20 minutes, 374 mls of a 12% w/w solution of sodium metabisulfite was added. The solution was filtered through a nylon filter, resuspended in a sodium dodecyl sulfate (SDS) solution, refiltered, and air dried to yield the gelatin particles with an approximate yield of 30%.
0015As was the case with Example 1 sodium metabisulfite solution was added to chemically reduce the remaining glutaraldehyde. The particle size distribution ranged generally from 0.1 microns to 5 microns.
0016The particles which had been subjected to the SDS treatment, were found to be easily dispersed in water without stirring and can be seen microscopically as individual spheres. The filter cake appears to contain SDS because upon the resuspension the weight of the new dry cake was reduced by 20%. A precipitate of barium dodecyl sulfate was formed when a solution of barium chloride was added to the filtrate. This cake is no longer dispersible in water. Preliminary experiments indicate that the particles thus formed are stable in 0.025% trypsin for several hours.
0017The use of SDS, of course, is not required when ethanol is used as the coacervating agent.
EXAMPLE 3
0018Coacervation of fish gelatin by sodium sulfite is performed around triamterine. Triamterine is a 6-phenyl-2, 4, 7-pteridinetriamine. It is a known diuretic. Three grams of 45% fish gelatin was dissolved in 27 ml of distilled water and 0.1g of Tramterine was dispersed in the distilled water along with the fish gelatin. 28 ml 20% w/w sodium sulfate was added over approximately 20 minutes and the suspension was filtered another 30 minutes. 0.5 ml diluted with water to 5% v/v solution of glutaraldehyde was added and, after 3.5 minutes, 30ml of sodium metabisulfite was added (12% w/w). The particles were filtered in a Whatman filter paper #541 and air dried. The particles appeared microscopically to be spheres of gelatin encircled drug and are quite distinct from the unencapsulated drug when subjected to a microscopic analysis. The filtered particles were air dried to a yellow aggregate weighing 0.25g., which was not easily dispersed in water. However, upon lyophilization and subsequent resuspension in water, they appear as microscopically discrete particles. Population particle size mean is 9.5u and the range is between 2.5 and 50u.
0019The examples set forth above are currently preferred examples of producing coaverated fish gelatin. Particle size integrity and yield may be affected by several aspects of the production of particles such as the addition rate of coacervating agents, the stirring speed, the presence or absence of surfactant, the time allowed for the development of the coacervate, the glutaraldehyde fixation conditions, the cross linking agent itself (if another is substituted or combined with glutaraldehyde), the sodium dodecyl sulfate wash concentration and the harvesting process. Obviously the particular choice of components, particle size, the presence of SDS or similar compounds will vary with the particular choice of drugs and the desired release rate. These variables are well within the skill of the art once the broad concept of this invention is set forth, namely the concept of coacervation of fish gelatin and the use of the coacervate as a protective coating for drug particles.
Contents5
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| WO2011060945A2 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| EP0542914A1 | Cited by | European Patent Office (EPO) | – | Search report |
| WO9620612A1 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| WO2011116962A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| US11395811B2 | Cited by | United States of America | – | Applicant |
| WO0212408A1 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| US10596142B2 | Cited by | United States of America | – | Applicant |
| US9192580B2 | Cited by | United States of America | – | Applicant |
| EP1165053A1 | Cited by | European Patent Office (EPO) | – | Search report |
| US11612579B2 | Cited by | United States of America | – | Applicant |
| EP1165053A4 | Cited by | European Patent Office (EPO) | – | Search report |
| US5348852A | Cited by | United States of America | – | Search report |
| WO2010103404A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| WO2007026307A2 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| US6709669B1 | Cited by | United States of America | – | Applicant |
| EP3915554A1 | Cited by | European Patent Office (EPO) | – | Applicant |
| WO2013072767A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| EP3578170A1 | Cited by | European Patent Office (EPO) | – | Applicant |
| WO2013150386A2 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| US10028928B2 | Cited by | United States of America | – | Applicant |
| US9708757B2 | Cited by | United States of America | – | Applicant |
| WO2013150384A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| ES2155395A1 | Cited by | Spain | – | Search report |
| WO2007026307A3 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| WO2006045865A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| US7309499B2 | Cited by | United States of America | – | Search report |
| WO2010119319A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| WO2011060943A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| WO2010103402A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| WO2011078712A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| US6423346B1 | Cited by | United States of America | – | Applicant |
| US9532963B2 | Cited by | United States of America | – | Applicant |
| WO2011060944A2 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| EP0542914A4 | Cited by | European Patent Office (EPO) | – | Search report |
| WO2012013331A2 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| US11351139B2 | Cited by | United States of America | – | Applicant |
| EP0038985A1 | Cites | European Patent Office (EPO) | Y | Search report |
| EP0038985A1 | Cites | European Patent Office (EPO) | Y | Search report |
| EP0130162A2 | Cites | European Patent Office (EPO) | Y | Search report |
| EP0130162A2 | Cites | European Patent Office (EPO) | Y | Search report |
| CHEMICAL ABSTRACTS, vol. 108, no. 8, 22nd February 1988, page 656, abstract no. 65887n, Columbus, Ohio, US; NORLAND PRODUCTS, INC.: "Small crystal formation using fish gelatin", & RES. DISCL. 1987, 284, 788 | Non-patent | – | – | Search report |
2 members in 2 offices; this record represents the family
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 207361 | United States of America | – | |
| 20736188 | United States of America | A | |
| US19880207361 | – | – | – |
| 207361 | – | – | – |
Members2
| Document | Office | Kind | |
|---|---|---|---|
| EP0346879A1This record | European Patent Office (EPO) | A1 | |
| US5035896A | United States of America | A |
6 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Application refused18R | 18R | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION HAS BEEN REFUSEDSTAA | STAA | |
| First examination report despatched17Q | 17Q | |
| Request for examination filed17P | 17P | |
| Designated contracting statesAK | AK | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 0346879
- Publication, DOCDB
- 0346879
- Publication, EPODOC
- EP0346879
- Application
- 891108185
- Application, DOCDB
- 89110818
- Application, EPODOC
- EP19890110818
Titles6
- German
- Wasserunlösliche, mit koazervierter Fischgelatine umhüllte Arzneimittel
- English
- Water insoluble drugs coated by coacervated fish gelatin
- French
- Médicaments insolubles dans l'eau et enrobés par coacervation avec de la gélatine de poisson
- German
- Wasserunlösliche, mit koazervierter Fischgelatine umhüllte Arzneimittel.
- English
- Water insoluble drugs coated by coacervated fish gelatin.
- French
- Médicaments insolubles dans l'eau et enrobés par coacervation avec de la gélatine de poisson.
Classification
- CPC, 3
- A61K9/5057
- Y10S514/801
- Y10S530/857
- IPC, 1
- A61K9 50
Designated states13
- Contracting states, 13
- Austria
- Belgium
- Switzerland
- Germany
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden